ÂÜÀòÂÒÂ×

Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health.  Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies.  As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company's second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr Whitehead holds a BA with honours from Oxford University.